


Q1 2025

Innovative Medicines to Extend Healthspan





Quantum Computing in Biotechnology

- 1. Revolutionizing Drug Discovery**

Quantum computing accelerates molecular simulations, predicts drug-protein interactions, and optimizes drug properties for faster, cost-effective development.
- 2. Unraveling Protein Folding**

Predict 3D protein structures with quantum precision, aiding in understanding diseases like Alzheimer's and creating therapeutic proteins.
- 3. Genomic Data Analysis**

Process vast genetic datasets rapidly, identify complex patterns, and enable personalized medicine tailored to genetic profiles.
- 4. Quantum-Classical Hybrid Systems**

Early integration of quantum and classical computing improves molecular modeling accuracy and drug discovery pipelines.
- 5. Quantum Sensors for Biology**


Achieve ultra-sensitive detection of biomolecules, enabling real-time cellular process monitoring and enhancing medical imaging.
- 6. Pioneering Bioinformatics**

Develop real-time genome analysis and advanced synthetic biology applications, including metabolic optimization and biomaterial innovation.

Digianalix

Juvenescence pipeline is now fully AI-enabled with integration of Ro5

For faster & more successful drug discovery and development



Rule of 5 - AI enabled drug discovery

Previously embedded in Reata Pharma and integral in SkyClaris approval for Friedreich's Ataxia

nature reviews drug discovery
FDA approves first Friedreich's ataxia drug



Rule of Five AI



Charles Knuff
Founding CEO



Aurimas Pabrinkis
ML Engineer



Tanya Paquet
Director Medicinal Chemistry



Sarah Flatters
Pharmacologist, Clinical Trials



Hisham Abdel Aty
Principal Computational Chemistry Scientist




Alvaro Prat
Principal Machine Learning Researcher



Slim Schults
Director Software Engineering


GLP1 agonists exemplify how a truly anti-ageing compound will upend the market

GLP1s central ageing mechanism
Weight loss, preventing diabetes, reducing CV complications, neuroprotective



Projected annual revenue for a truly anti-ageing compound (\$200 billion) compared to projected revenue of best-selling existing drugs

Comparing past and future projected best selling drugs of all time




Source: AGE1 TAM model https://www.librariesforthefuture.bio/p/tam-aging-drug?subscribe_prompt=free

age1

Top 5 assets in the Juv pipeline deliver multiple clinical starts 2024/5

Monetisation potential from Phase 1



*We are conducting a Phase 0 human study with our Ketone Rx product, dosing people from June 2024.

 First potential monetisation points

FIC First-in-class medicines target a new and unique mechanism of action for treating a disease.

BIC Best-in-class medicines are considered 'fast followers' targeting the same mechanisms as existing medicines, however, with therapeutic superiority or a more favourable safety profile.


Game changing regenerative approaches to severe loss of tissue function



Bioelectric Induction of Limb Regeneration



We can grow innervated, functioning limbs after just 1 hour of electroceutical exposure

Limb outgrowth & patterning induced – regenerated limb has both sensation & mobility



Phase 2 trial ongoing of organ transplant alternative

Cell transplantation into lymph nodes via outpatient ultrasound generates functional liver tissue





Jim Mellon